Business
Conavi Medical to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: C...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceToronto, Ontario--(Newsfile Corp. - April 25, 2025) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (\"Conavi\" or the \"Company\"), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025.Details on the presentation are as follows:Date: Tuesday, May 6, 2025Time: 3:00 p.m. Eastern Time Location: Metro Toronto Convention Centre, Toronto Webcast: https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/cnYwKD5CoHUUJVeVinaQyEWebcast and replay information for this event will also be available on the Investor Relations section of Conavi's website at https://www.conavi.com/novasight/investor-information . The replay will be available for 90 days.The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: bloomburton.com/conference.About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit conavi.com.Notice on forward-looking statements:This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regard...